학술논문
Risk factors and outcome of COVID-19 in patients with hematological malignancies
Document Type
article
Author
José Luis Piñana; Rodrigo Martino; Irene García-García; Rocío Parody; María Dolores Morales; Gonzalo Benzo; Irene Gómez-Catalan; Rosa Coll; Ignacio De La Fuente; Alejandro Luna; Beatriz Merchán; Anabelle Chinea; Dunia de Miguel; Ana Serrano; Carmen Pérez; Carola Diaz; José Luis Lopez; Adolfo Jesús Saez; Rebeca Bailen; Teresa Zudaire; Diana Martínez; Manuel Jurado; María Calbacho; Lourdes Vázquez; Irene Garcia-Cadenas; Laura Fox; Ana I. Pimentel; Guiomar Bautista; Agustin Nieto; Pascual Fernandez; Juan Carlos Vallejo; Carlos Solano; Marta Valero; Ildefonso Espigado; Raquel Saldaña; Luisa Sisinni; Josep Maria Ribera; Maria Jose Jimenez; Maria Trabazo; Marta Gonzalez-Vicent; Noemí Fernández; Carme Talarn; Maria Carmen Montoya; Angel Cedillo; Anna Sureda; Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH)
Source
Experimental Hematology & Oncology, Vol 9, Iss 1, Pp 1-16 (2020)
Subject
Language
English
ISSN
2162-3619
Abstract
Abstract Background Prognostic factors of poor outcome in patients with hematological malignancies and COVID-19 are poorly defined. Patients and methods This was a Spanish transplant group and cell therapy (GETH) multicenter retrospective observational study, which included a large cohort of blood cancer patients with laboratory-confirmed SARS-CoV-2 infection through PCR assays from March 1st 2020 to May 15th 2020. Results We included 367 pediatric and adult patients with hematological malignancies, including recipients of autologous (ASCT) (n = 58) or allogeneic stem cell transplantation (allo-SCT) (n = 65) from 41 hospitals in Spain. Median age of patients was 64 years (range 1–93.8). Recipients of ASCT and allo-SCT showed lower mortality rates (17% and 18%, respectively) compared to non-SCT patients (31%) (p = 0.02). Prognostic factors identified for day 45 overall mortality (OM) by logistic regression multivariate analysis included age > 70 years [odds ratio (OR) 2.1, 95% confidence interval (CI) 1.2–3.8, p = 0.011]; uncontrolled hematological malignancy (OR 2.9, 95% CI 1.6–5.2, p 20 mg/dL (OR 3.3, 95% CI 1.7–6.4, p